首页 > 最新文献

Revista De Investigacion Clinica-Clinical and Translational Investigation最新文献

英文 中文
Transjugular Random Renal Biopsy: A Review. 经颈静脉随机肾活检:综述。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000163
Gill Katelyn, Laney Iv Dan F, Ferral Hector

Unassigned: Random renal biopsy is considered the gold standard for the diagnosis of systemic renal disorders. Percutaneous biopsy remains a safe option for most patients; however, the percutaneous approach may be considered too risky in approximately 5-10% of patients. In these high-risk patients, transjugular renal biopsy (TJRB) may represent an underutilized alternative. TJRB is a technically difficult procedure with a learning curve of approximately 10 cases. When performed properly, TJRB is a safe alternative to percutaneous biopsy in patients with renal failure or who are at high risk of bleeding. This article aims to provide a comprehensive review of the indications, techniques, precautions, and complications of TJRB, a possibly underutilized technique. (Rev Invest Clin. 2024;76(5):207-12).

未指定:随机肾活检被认为是诊断全身性肾脏疾病的金标准。对于大多数患者来说,经皮活检仍是一种安全的选择;然而,在大约 5-10% 的患者中,经皮方法可能被认为风险过高。在这些高风险患者中,经颈静脉肾活检(TJRB)可能是一种未得到充分利用的替代方法。经颈静脉肾活检是一项技术难度较高的手术,学习曲线约为 10 例。如果操作得当,对于肾功能衰竭或出血风险高的患者来说,TJRB 是经皮活检的安全替代方法。本文旨在对 TJRB 这一可能未得到充分利用的技术的适应症、技术、注意事项和并发症进行全面综述。(Rev Invest Clin.2024;76(5):207-12).
{"title":"Transjugular Random Renal Biopsy: A Review.","authors":"Gill Katelyn, Laney Iv Dan F, Ferral Hector","doi":"10.24875/RIC.24000163","DOIUrl":"10.24875/RIC.24000163","url":null,"abstract":"<p><strong>Unassigned: </strong>Random renal biopsy is considered the gold standard for the diagnosis of systemic renal disorders. Percutaneous biopsy remains a safe option for most patients; however, the percutaneous approach may be considered too risky in approximately 5-10% of patients. In these high-risk patients, transjugular renal biopsy (TJRB) may represent an underutilized alternative. TJRB is a technically difficult procedure with a learning curve of approximately 10 cases. When performed properly, TJRB is a safe alternative to percutaneous biopsy in patients with renal failure or who are at high risk of bleeding. This article aims to provide a comprehensive review of the indications, techniques, precautions, and complications of TJRB, a possibly underutilized technique. (Rev Invest Clin. 2024;76(5):207-12).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 5","pages":"207-212"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in Sleep Quality in Patients Older than 60 Years, Post-COVID Pandemic. covid - 19大流行后60岁以上患者睡眠质量变化
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000180
Ramírez-Mexia Manuel R, Martínez-Rodríguez Yamile, Sierra-Lara Mayomi, Espinosa-Arellano Andrea, Buendía-Roldán Ivette

Unassigned: Background: COVID-19 is a disease that had a great impact in the world, generating lifestyle changes; among these are changes in sleep quality, with the elderly being one of the most affected age groups. Objective: To identify sleep alterations in Mexican people older than 60 years post COVID-19 pandemic. Methods: We performed a descriptive study on subjects older than 60 years from the aging cohort of the National Institute of Respiratory Diseases. Demographic data, sleep questionnaires (Pittsburgh), and quality of life (SF-12) were assessed pre-pandemic. During the period from June 2021 to August 2022, the questionnaires were repeated post-pandemic through telephone. Qualitative variables were analyzed with frequencies and percentages, whereas quantitative variables were analyzed with means and standard deviations. The groups were compared using the X2 test and Student's t-test. Results: We analyzed 279 subjects who completed two questionnaires. An alteration in sleep quality variables was observed post-COVID, including a decrease in sleep hours (7.33 h versus 7.17 h, p = 0.03), and a trend to a longer time to fall asleep (23 m vs 27 m, p = 0.06). In the questionnaire on toxicology, we found higher alcohol consumption (18% vs. 27%, p = 0.01) and vitamin ingestion (34% vs. 46%, p = 0.003). Subjects also described more nighttime awakenings, with more than 3 times per week (25% vs. 44%, p < 0.0001), generating a worse auto perception of healthy well-being (88.3 vs. 82.02 p < 0.0001). Conclusions: The COVID-19 pandemic affected sleep quality in different aspects, and it increased the consumption of alcohol and vitamins. (Rev Invest Clin. 2024;76(6):239-42).

背景:COVID-19是一种对世界产生巨大影响的疾病,导致生活方式发生改变;其中包括睡眠质量的变化,老年人是受影响最大的年龄组之一。目的:确定60岁以上墨西哥人在COVID-19大流行后的睡眠变化。方法:我们对来自国家呼吸疾病研究所老年队列的60岁以上的受试者进行了一项描述性研究。大流行前对人口统计数据、睡眠问卷(匹兹堡)和生活质量(SF-12)进行了评估。在2021年6月至2022年8月期间,大流行后通过电话重复了问卷调查。定性变量采用频率和百分比分析,定量变量采用均值和标准差分析。组间比较采用X2检验和学生t检验。结果:我们分析了279名受试者,他们完成了两份问卷。新冠肺炎后观察到睡眠质量变量的变化,包括睡眠时间减少(7.33 h对7.17 h, p = 0.03),入睡时间延长(23 m对27 m, p = 0.06)。在毒理学调查问卷中,我们发现饮酒(18%对27%,p = 0.01)和维生素摄入(34%对46%,p = 0.003)较高。受试者还描述了更多的夜间醒来,每周超过3次(25%对44%,p < 0.0001),产生了更差的健康幸福感的自动感知(88.3对82.02 p < 0.0001)。结论:新冠肺炎疫情对睡眠质量的影响是多方面的,增加了酒精和维生素的消耗。[j] .投资与临床,2024;76(6):239-42。
{"title":"Changes in Sleep Quality in Patients Older than 60 Years, Post-COVID Pandemic.","authors":"Ramírez-Mexia Manuel R, Martínez-Rodríguez Yamile, Sierra-Lara Mayomi, Espinosa-Arellano Andrea, Buendía-Roldán Ivette","doi":"10.24875/RIC.24000180","DOIUrl":"https://doi.org/10.24875/RIC.24000180","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: COVID-19 is a disease that had a great impact in the world, generating lifestyle changes; among these are changes in sleep quality, with the elderly being one of the most affected age groups. Objective: To identify sleep alterations in Mexican people older than 60 years post COVID-19 pandemic. Methods: We performed a descriptive study on subjects older than 60 years from the aging cohort of the National Institute of Respiratory Diseases. Demographic data, sleep questionnaires (Pittsburgh), and quality of life (SF-12) were assessed pre-pandemic. During the period from June 2021 to August 2022, the questionnaires were repeated post-pandemic through telephone. Qualitative variables were analyzed with frequencies and percentages, whereas quantitative variables were analyzed with means and standard deviations. The groups were compared using the X<sup>2</sup> test and Student's t-test. Results: We analyzed 279 subjects who completed two questionnaires. An alteration in sleep quality variables was observed post-COVID, including a decrease in sleep hours (7.33 h versus 7.17 h, p = 0.03), and a trend to a longer time to fall asleep (23 m vs 27 m, p = 0.06). In the questionnaire on toxicology, we found higher alcohol consumption (18% vs. 27%, p = 0.01) and vitamin ingestion (34% vs. 46%, p = 0.003). Subjects also described more nighttime awakenings, with more than 3 times per week (25% vs. 44%, p < 0.0001), generating a worse auto perception of healthy well-being (88.3 vs. 82.02 p < 0.0001). Conclusions: The COVID-19 pandemic affected sleep quality in different aspects, and it increased the consumption of alcohol and vitamins. (Rev Invest Clin. 2024;76(6):239-42).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 6","pages":"239-242"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later. 酪氨酸激酶抑制剂时代墨西哥噬菌体阳性慢性骨髓性白血病患者的治疗选择:干细胞移植还是酪氨酸激酶抑制剂?十五年后。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000274
Max Robles-Nasta, Daniela Sánchez-Bonilla, Moisés M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles

Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias. Tyrosine-kinase inhibitors are considered front-line therapy in high-income countries, whereas allogeneic hematopoietic stem cell transplantation is a recognized therapeutic approach, mainly in low- and middle-income countries.

Objective: To analyze the overall survival of persons with chronic myelogenous leukemia who have received tyrosine-kinase inhibitors or allogeneic hematopoietic stem cell transplantation in a medical center, since 1994, and briefly discuss the current indications of these treatments in the tyrosine-kinase inhibitors era.

Methods: We retrospectively analyzed all patients with a diagnosis of chronic myelogenous leukemia treated in a medical center between 1994 and 2023; subsets of individuals who received an allogeneic hematopoietic stem cell transplantation or tyrosine-kinase inhibitors therapy as first-line treatment were analyzed.

Results: 60 persons with chronic myelogenous leukemia were treated with allogeneic hematopoietic stem cell transplantation or tyrosine-kinase inhibitors: 35 received an allogeneic hematopoietic stem cell transplantation, whereas 25 were given tyrosine-kinase inhibitors. All patients who underwent an allogeneic hematopoietic stem cell transplantation engrafted successfully, and the procedure was completed on an outpatient basis in most cases (29/35). The median survival in allogeneic hematopoietic stem cell transplantation was 78.3 months (CI 95%: 0-205.6) and in persons given tyrosine-kinase inhibitors the median was not reached.

Conclusion: Tyrosine-kinase inhibitors were significantly superior to allogeneic hematopoietic stem cell transplantation in prolonging the overall survival of persons with chronic myelogenous leukemia in our single institution experience.

未分配:背景:慢性粒细胞白血病是粒细胞系列的肿瘤性增生。在墨西哥,慢性粒细胞白血病约占所有白血病的 10%。在高收入国家,酪氨酸激酶抑制剂被视为一线疗法,而异体造血干细胞移植则是公认的治疗方法,主要在中低收入国家。研究目的分析一家医疗中心自1994年以来接受酪氨酸激酶抑制剂或异体造血干细胞移植治疗的慢性骨髓性白血病患者的总生存率,并简要讨论在酪氨酸激酶抑制剂时代这些治疗方法的当前适应症。方法我们回顾性分析了1994年至2023年间在一家医疗中心接受治疗的所有诊断为慢性粒细胞性白血病的患者;分析了接受异基因造血干细胞移植或酪氨酸激酶抑制剂治疗作为一线治疗的患者子集。结果60名慢性骨髓性白血病患者接受了异基因造血干细胞移植或酪氨酸激酶抑制剂治疗:35人接受了异基因造血干细胞移植,25人接受了酪氨酸激酶抑制剂治疗。所有接受异基因造血干细胞移植的患者都成功进行了移植,而且大多数患者(29/35)的移植手术都是在门诊完成的。异基因造血干细胞移植的中位生存期为78.3个月(CI 95%:0-205.6个月),而使用酪氨酸激酶抑制剂的患者未达到中位生存期。结论在我们单个机构的经验中,酪氨酸激酶抑制剂在延长慢性骨髓性白血病患者总生存期方面明显优于异基因造血干细胞移植。(Rev Invest Clin.2024;76(2):91-6).
{"title":"Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later.","authors":"Max Robles-Nasta, Daniela Sánchez-Bonilla, Moisés M. Gallardo-Pérez, Edgar J. Hernández-Flores, Merittzel A. Montes-Robles, María de L. Pastelín-Martínez, Juan C. Olivares-Gazca, Guillermo J. Ruiz-Delgado, Guillermo J. Ruiz-Argüelles","doi":"10.24875/RIC.23000274","DOIUrl":"10.24875/RIC.23000274","url":null,"abstract":"<p><strong>Background: </strong>Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias. Tyrosine-kinase inhibitors are considered front-line therapy in high-income countries, whereas allogeneic hematopoietic stem cell transplantation is a recognized therapeutic approach, mainly in low- and middle-income countries.</p><p><strong>Objective: </strong>To analyze the overall survival of persons with chronic myelogenous leukemia who have received tyrosine-kinase inhibitors or allogeneic hematopoietic stem cell transplantation in a medical center, since 1994, and briefly discuss the current indications of these treatments in the tyrosine-kinase inhibitors era.</p><p><strong>Methods: </strong>We retrospectively analyzed all patients with a diagnosis of chronic myelogenous leukemia treated in a medical center between 1994 and 2023; subsets of individuals who received an allogeneic hematopoietic stem cell transplantation or tyrosine-kinase inhibitors therapy as first-line treatment were analyzed.</p><p><strong>Results: </strong>60 persons with chronic myelogenous leukemia were treated with allogeneic hematopoietic stem cell transplantation or tyrosine-kinase inhibitors: 35 received an allogeneic hematopoietic stem cell transplantation, whereas 25 were given tyrosine-kinase inhibitors. All patients who underwent an allogeneic hematopoietic stem cell transplantation engrafted successfully, and the procedure was completed on an outpatient basis in most cases (29/35). The median survival in allogeneic hematopoietic stem cell transplantation was 78.3 months (CI 95%: 0-205.6) and in persons given tyrosine-kinase inhibitors the median was not reached.</p><p><strong>Conclusion: </strong>Tyrosine-kinase inhibitors were significantly superior to allogeneic hematopoietic stem cell transplantation in prolonging the overall survival of persons with chronic myelogenous leukemia in our single institution experience.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 2","pages":"91-96"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Smoking with Disease Progression in Persons with Multiple Sclerosis Undergoing Autologous Hematopoietic Cell Transplantation: A Single-Center Experience. 接受自体造血细胞移植的多发性硬化症患者吸烟与疾病进展的关系:单中心经验
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000203
Fernández-Lara Danitza, Porcel José M, Robles-Hernández Robinson, Lira-Lara Olivia, Melgar-de-la-Paz Miranda, Gallardo-Pérez Moisés Manuel, Olivares-Gazca Juan C, Ruiz-Delgado Guillermo J, Ruiz-Argüelles Guillermo J

Unassigned: Background: Smoking remains a significant issue that increases the prevalence of multiple sclerosis (MS) and its progression to secondary progressive forms. Objectives: The goal is to identify the relationship between smoking and disease progression in MS patients who have undergone autologous hematopoietic stem cell transplantation (auto-HSCT) at the Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico. Methods: This retrospective study involved MS patients treated with auto-HSCT, followed for 12 months. The response to transplantation was measured using the difference in Expanded Disability Status Scale (EDSS) scores before and 12 months after the transplant. A difference of -0.5 or greater indicated a good response, while a difference below 0.5 indicated a poor response. Results: The study included 419 patients, with a median age of 47 years (IQR: 40-53). The majority were non-smokers (315) compared to smokers/ex-smokers (104). In patients with PMSS, EDSS stabilization at 12 months was observed in both smokers/ex-smokers (median 6, interquartile range (IQR) = 1 vs. 6, IQR = 1, p = 0.466) and non-smokers (median 6, IQR = 1 vs. 6, IQR = 1.5, p = 0.001), although non-smokers showed a statistically significant difference. Conclusion: Smoking may negatively impact MS progression, especially in its progressive forms. (Rev Invest Clin. 2024;76(5):223-9).

未分配:背景:吸烟仍然是一个重要问题,它会增加多发性硬化症(MS)的发病率,并使其发展为继发性进展。研究目的目的:在墨西哥普埃布拉鲁伊斯诊所血液学与国际医学中心(Centro de Hematología y Medicina Interna)接受自体造血干细胞移植(auto-HSCT)的多发性硬化症患者中,确定吸烟与疾病进展之间的关系。方法:这项回顾性研究涉及接受自体供体移植治疗的多发性硬化症患者,随访时间为 12 个月。移植后的反应通过移植前和移植后12个月的扩展残疾状态量表(EDSS)评分差异来衡量。差值在-0.5或以上表示反应良好,差值在0.5以下表示反应不佳。研究结果研究共纳入 419 名患者,中位年龄为 47 岁(IQR:40-53)。大多数患者为非吸烟者(315 人),而吸烟者/戒烟者为 104 人。在 PMSS 患者中,吸烟者/戒烟者(中位数 6,四分位数间距 (IQR) = 1 vs. 6,IQR = 1,p = 0.466)和非吸烟者(中位数 6,四分位数间距 (IQR) = 1 vs. 6,IQR = 1.5,p = 0.001)的 EDSS 在 12 个月后均趋于稳定,但非吸烟者之间的差异具有统计学意义。结论吸烟可能对多发性硬化症的进展产生负面影响,尤其是进展期多发性硬化症。(Rev Invest Clin.2024;76(5):223-9).
{"title":"Association of Smoking with Disease Progression in Persons with Multiple Sclerosis Undergoing Autologous Hematopoietic Cell Transplantation: A Single-Center Experience.","authors":"Fernández-Lara Danitza, Porcel José M, Robles-Hernández Robinson, Lira-Lara Olivia, Melgar-de-la-Paz Miranda, Gallardo-Pérez Moisés Manuel, Olivares-Gazca Juan C, Ruiz-Delgado Guillermo J, Ruiz-Argüelles Guillermo J","doi":"10.24875/RIC.24000203","DOIUrl":"10.24875/RIC.24000203","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: Smoking remains a significant issue that increases the prevalence of multiple sclerosis (MS) and its progression to secondary progressive forms. Objectives: The goal is to identify the relationship between smoking and disease progression in MS patients who have undergone autologous hematopoietic stem cell transplantation (auto-HSCT) at the Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico. Methods: This retrospective study involved MS patients treated with auto-HSCT, followed for 12 months. The response to transplantation was measured using the difference in Expanded Disability Status Scale (EDSS) scores before and 12 months after the transplant. A difference of -0.5 or greater indicated a good response, while a difference below 0.5 indicated a poor response. Results: The study included 419 patients, with a median age of 47 years (IQR: 40-53). The majority were non-smokers (315) compared to smokers/ex-smokers (104). In patients with PMSS, EDSS stabilization at 12 months was observed in both smokers/ex-smokers (median 6, interquartile range (IQR) = 1 vs. 6, IQR = 1, p = 0.466) and non-smokers (median 6, IQR = 1 vs. 6, IQR = 1.5, p = 0.001), although non-smokers showed a statistically significant difference. Conclusion: Smoking may negatively impact MS progression, especially in its progressive forms. (Rev Invest Clin. 2024;76(5):223-9).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 5","pages":"223-229"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The rs1477196 SNP of the FTO Gene is Associated with Primary Knee Osteoarthritis in a Female Population from Northern Mexico. 在墨西哥北部的一个女性群体中,FTO 基因的 rs1477196 SNP 与原发性膝骨关节炎有关。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000259
Rubén D Arellano-Pérez-Vertti, Faviel F González-Galarza, Denisse Prone-Olazábal, Daniel O Arellano-Ramírez, Diego F Arellano-Ramírez, Cristina S Argüello-Beltrán, Michelle A Tovar-Aguilar, Mónica Berúmen-Rodríguez, Adria I Prieto-Hinojosa, Alejandra Méndez-Hernández, Rafael Argüello-Astorga

Background: Osteoarthritis is a frequent rheumatic disease. Some single-nucleotide polymorphisms of the gene associated with fat mass and obesity are associated with increased body mass index and knee osteoarthritis.

Objective: The objective of this study was to analyze the association of single nucleotide polymorphism rs1477196 of the fat mass and obesity gene with primary knee osteoarthritis.

Methods: This observational and cross-sectional study included 347 Mexican participants. We performed the genotypification analysis with TaqMan® probe C_2031262_10 for rs1477196 (Thermo Fisher Scientific). Multivariate analysis included covariables such as age, type 2 diabetes, obesity, and postmenopause.

Results: Type 2 diabetes, obesity, and postmenopause were associated with primary knee osteoarthritis in female participants. We did not find an association between rs1477196 and obesity. In the codominant and dominant genetic models, rs1477196 was significantly associated with primary knee osteoarthritis only in the female group, including in the model adjusted by other covariables (odds ratio = 2.517; 1.035-6.123; p = 0.042 and odds ratio = 2.387; 1.054-5.407; p = 0.037, respectively). The interaction between rs1477196 and obesity was significantly associated with primary knee osteoarthritis in female participants (p = 0.039 and p = 0.043).

Conclusions: Our findings suggest that the rs1477196 variant of the fat and obesity mass gene may be associated with the risk of primary knee osteoarthritis in women.

未分配:背景:骨关节炎是一种常见的风湿性疾病。一些与脂肪量和肥胖有关的单核苷酸多态性基因与体重指数增加和膝骨关节炎有关。研究目的本研究旨在分析脂肪量和肥胖基因的单核苷酸多态性 rs1477196 与原发性膝骨关节炎的相关性。研究方法这项观察性横断面研究纳入了 347 名墨西哥参与者。我们使用 TaqMan® 探针 C_2031262_10 对 rs1477196 (赛默飞世尔科技公司)进行了基因分型分析。多变量分析包括年龄、2 型糖尿病、肥胖和绝经后等协变量。结果2型糖尿病、肥胖和绝经后与女性参与者的原发性膝骨关节炎有关。我们没有发现 rs1477196 与肥胖有关。在共显性和显性遗传模型中,rs1477196 仅与女性组的原发性膝骨关节炎显著相关,包括在经其他协变量调整的模型中(几率比分别为 2.517; 1.035-6.123; p = 0.042 和几率比分别为 2.387; 1.054-5.407; p = 0.037)。在女性参与者中,rs1477196与肥胖之间的交互作用与原发性膝骨关节炎显著相关(p = 0.039 和 p = 0.043)。结论我们的研究结果表明,脂肪和肥胖质量基因的 rs1477196 变体可能与女性原发性膝骨关节炎的风险有关。(Rev invest clin.2024;76(1):37-44).
{"title":"The rs1477196 SNP of the FTO Gene is Associated with Primary Knee Osteoarthritis in a Female Population from Northern Mexico.","authors":"Rubén D Arellano-Pérez-Vertti, Faviel F González-Galarza, Denisse Prone-Olazábal, Daniel O Arellano-Ramírez, Diego F Arellano-Ramírez, Cristina S Argüello-Beltrán, Michelle A Tovar-Aguilar, Mónica Berúmen-Rodríguez, Adria I Prieto-Hinojosa, Alejandra Méndez-Hernández, Rafael Argüello-Astorga","doi":"10.24875/RIC.23000259","DOIUrl":"10.24875/RIC.23000259","url":null,"abstract":"<p><strong>Background: </strong>Osteoarthritis is a frequent rheumatic disease. Some single-nucleotide polymorphisms of the gene associated with fat mass and obesity are associated with increased body mass index and knee osteoarthritis.</p><p><strong>Objective: </strong>The objective of this study was to analyze the association of single nucleotide polymorphism rs1477196 of the fat mass and obesity gene with primary knee osteoarthritis.</p><p><strong>Methods: </strong>This observational and cross-sectional study included 347 Mexican participants. We performed the genotypification analysis with TaqMan® probe C_2031262_10 for rs1477196 (Thermo Fisher Scientific). Multivariate analysis included covariables such as age, type 2 diabetes, obesity, and postmenopause.</p><p><strong>Results: </strong>Type 2 diabetes, obesity, and postmenopause were associated with primary knee osteoarthritis in female participants. We did not find an association between rs1477196 and obesity. In the codominant and dominant genetic models, rs1477196 was significantly associated with primary knee osteoarthritis only in the female group, including in the model adjusted by other covariables (odds ratio = 2.517; 1.035-6.123; p = 0.042 and odds ratio = 2.387; 1.054-5.407; p = 0.037, respectively). The interaction between rs1477196 and obesity was significantly associated with primary knee osteoarthritis in female participants (p = 0.039 and p = 0.043).</p><p><strong>Conclusions: </strong>Our findings suggest that the rs1477196 variant of the fat and obesity mass gene may be associated with the risk of primary knee osteoarthritis in women.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 1","pages":"37-44"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140040720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of Prognostic Features Based on Neutrophil-Related Genes for Lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates. 基于中性粒细胞相关基因的肺鳞癌预后特征预测揭示了免疫格局和候选药物
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000262
Du Sili, Zhang Nan

Unassigned: Background: Since to the prognosis of lung squamous cell carcinoma is generally poor, there is an urgent need to innovate new prognostic biomarkers and therapeutic targets to improve patient outcomes. Objectives: Our goal was to develop a novel multi-gene prognostic model linked to neutrophils for predicting lung squamous cell carcinoma prognosis. Methods: We utilized messenger RNA expression profiles and relevant clinical data of lung squamous cell carcinoma patients from the Cancer Genome Atlas database. Through K-means clustering, least absolute shrinkage and selection operator regression, and univariate/multivariate Cox regression analyses, we identified 12 neutrophil-related genes strongly related to patient survival and constructed a prognostic model. We verified the stability of the model in the Cancer Genome Atlas database and gene expression omnibus validation set, demonstrating the robust predictive performance of the model. Results: Immunoinfiltration analysis revealed remarkably elevated levels of infiltration for natural killer cells resting and monocytes in the high-risk group compared to the low-risk group, while macrophages had considerably lower infiltration in the high risk group. Most immune checkpoint genes, including programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4, exhibited high expression levels in the high risk group. Tumor immune dysfunction and exclusion scores and immunophenoscore results suggested a potential inclination toward immunotherapy in the "RIC" version V2 revised high risk group. Moreover, prediction results from the CellMiner database revealed great correlations between drug sensitivity (e.g., Vinorelbine and PKI-587) and prognostic genes. Conclusion: Overall, our study established a reliable prognostic risk model that possessed significant value in predicting the overall survival of lung squamous cell carcinoma patients and may guide personalized treatment strategies. (Rev Invest Clin. 2024;76(2):116-31).

未分配:背景:由于肺鳞状细胞癌的预后普遍较差,因此迫切需要创新新的预后生物标志物和治疗靶点,以改善患者的预后。研究目标我们的目标是开发一种与中性粒细胞相关的新型多基因预后模型,用于预测肺鳞癌的预后。方法我们利用癌症基因组图谱数据库中肺鳞状细胞癌患者的信使 RNA 表达谱和相关临床数据。通过 K-均值聚类、最小绝对收缩和选择算子回归以及单变量/多变量 Cox 回归分析,我们确定了与患者生存密切相关的 12 个中性粒细胞相关基因,并构建了一个预后模型。我们在癌症基因组图谱数据库和基因表达总括验证集中验证了该模型的稳定性,证明了该模型稳健的预测性能。结果免疫浸润分析表明,与低风险组相比,高风险组的自然杀伤细胞和单核细胞浸润水平明显升高,而巨噬细胞在高风险组的浸润水平要低得多。大多数免疫检查点基因,包括程序性细胞死亡蛋白1和细胞毒性T淋巴细胞相关抗原4,在高风险组中都表现出较高的表达水平。肿瘤免疫功能障碍和排斥评分以及免疫表观评分结果表明,"RIC "版 V2 修订版高风险组可能倾向于免疫疗法。此外,CellMiner 数据库的预测结果显示,药物敏感性(如长春瑞滨和 PKI-587)与预后基因之间存在很大的相关性。结论总之,我们的研究建立了一个可靠的预后风险模型,该模型在预测肺鳞癌患者的总体生存期方面具有重要价值,并可指导个性化治疗策略。(Rev Invest Clin.2024;76(2):116-31).
{"title":"Prediction of Prognostic Features Based on Neutrophil-Related Genes for Lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates.","authors":"Du Sili, Zhang Nan","doi":"10.24875/RIC.23000262","DOIUrl":"https://doi.org/10.24875/RIC.23000262","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: Since to the prognosis of lung squamous cell carcinoma is generally poor, there is an urgent need to innovate new prognostic biomarkers and therapeutic targets to improve patient outcomes. Objectives: Our goal was to develop a novel multi-gene prognostic model linked to neutrophils for predicting lung squamous cell carcinoma prognosis. Methods: We utilized messenger RNA expression profiles and relevant clinical data of lung squamous cell carcinoma patients from the Cancer Genome Atlas database. Through K-means clustering, least absolute shrinkage and selection operator regression, and univariate/multivariate Cox regression analyses, we identified 12 neutrophil-related genes strongly related to patient survival and constructed a prognostic model. We verified the stability of the model in the Cancer Genome Atlas database and gene expression omnibus validation set, demonstrating the robust predictive performance of the model. Results: Immunoinfiltration analysis revealed remarkably elevated levels of infiltration for natural killer cells resting and monocytes in the high-risk group compared to the low-risk group, while macrophages had considerably lower infiltration in the high risk group. Most immune checkpoint genes, including programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4, exhibited high expression levels in the high risk group. Tumor immune dysfunction and exclusion scores and immunophenoscore results suggested a potential inclination toward immunotherapy in the \"RIC\" version V2 revised high risk group. Moreover, prediction results from the CellMiner database revealed great correlations between drug sensitivity (e.g., Vinorelbine and PKI-587) and prognostic genes. Conclusion: Overall, our study established a reliable prognostic risk model that possessed significant value in predicting the overall survival of lung squamous cell carcinoma patients and may guide personalized treatment strategies. (Rev Invest Clin. 2024;76(2):116-31).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 2","pages":"116-131"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment. 有认知障碍的老年人脑脊液生物标记物、脑18-氟脱氧葡萄糖PET与临床诊断之间的一致性
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000161
Mimenza-Alvarado Alberto J, León-Del-Ángel Karen G, Hernández-Ramírez Rodrigo, Rodríguez-Callejas Juan de D, Yeverino-Castro Sara G, Aguilar-Navarro Sara G

Unassigned: Background: Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer's disease (AD) and other dementias. Objective: To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal fluid (CSF) and [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) biomarkers in a cohort of patients from a memory clinic. Methods: This is a observational, retrospective, cohort study conducted at an outpatient memory clinic. Between July 2018 and September 2023, data from adults' ≥ 55 years with a mild cognitive impairment or dementia diagnosis without etiological diagnosis were obtained, complemented with the evaluation of biomarkers in CSF and [18F] FDG-PET biomarker assessment were included. Kappa coefficients (κ) were used to establish the level of agreement between CSF and [18F] FDG-PET results. Results: Seventy-seven patients had an available [18F] FDG-PET scan, and 25 (32.5%) had both biomarkers. We observed a fair-to-moderate diagnostic agreement between patients' initial and their final diagnosis in the presence of CSF (κ = 0.233, 95% confidence interval [CI]: -0.099-0.566) and [18F] FDG-PET (κ = 0.451, 95% CI: 0.277-0.625, p < 0.001) results. The Kappa value for diagnostic concordance between [18F] FDG-PET and CSF to differentiate between AD and other dementias was 0.733 (95% CI: 0.425-1.000, p < 0.005). Conclusion: This study demonstrates good agreement between the CSF and FDG-PET biomarkers to differentiate AD from other dementias. (Rev Invest Clin. 2024;76(5):230-7).

未分配:背景:临床实践中,阿尔茨海默病(AD)和其他痴呆症的临床标准与生物标志物相结合的诊断方法已取得进展。目的在记忆诊所的一组患者中确定初步临床诊断与脑脊液(CSF)和[18F]-氟脱氧葡萄糖(FDG)-正电子发射断层扫描(PET)生物标记物之间的诊断一致性水平。方法:这是一项在记忆门诊进行的观察性、回顾性队列研究。在 2018 年 7 月至 2023 年 9 月期间,获得了年龄≥ 55 岁、有轻度认知障碍或痴呆诊断但无病因诊断的成年人的数据,并对 CSF 中的生物标志物进行了评估,同时纳入了[18F] FDG-PET 生物标志物评估。卡帕系数(κ)用于确定脑脊液和[18F] FDG-PET结果之间的一致程度。结果77名患者接受了[18F] FDG-PET扫描,其中25名患者(32.5%)同时接受了两种生物标记物的扫描。我们观察到,在 CSF(κ = 0.233,95% 置信区间 [CI]:-0.099-0.566)和 [18F] FDG-PET (κ = 0.451,95% 置信区间 [CI]:0.277-0.625,p < 0.001)结果存在的情况下,患者的初步诊断与最终诊断之间存在相当到中等程度的诊断一致性。[18F]FDG-PET和CSF在区分AD和其他痴呆症方面的诊断一致性Kappa值为0.733(95% CI:0.425-1.000,p <0.005)。结论本研究表明,CSF 和 FDG-PET 生物标记物在区分 AD 和其他痴呆症方面具有良好的一致性。(Rev Invest Clin.2024;76(5):230-7).
{"title":"Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment.","authors":"Mimenza-Alvarado Alberto J, León-Del-Ángel Karen G, Hernández-Ramírez Rodrigo, Rodríguez-Callejas Juan de D, Yeverino-Castro Sara G, Aguilar-Navarro Sara G","doi":"10.24875/RIC.24000161","DOIUrl":"10.24875/RIC.24000161","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer's disease (AD) and other dementias. Objective: To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal fluid (CSF) and [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) biomarkers in a cohort of patients from a memory clinic. Methods: This is a observational, retrospective, cohort study conducted at an outpatient memory clinic. Between July 2018 and September 2023, data from adults' ≥ 55 years with a mild cognitive impairment or dementia diagnosis without etiological diagnosis were obtained, complemented with the evaluation of biomarkers in CSF and [18F] FDG-PET biomarker assessment were included. Kappa coefficients (κ) were used to establish the level of agreement between CSF and [18F] FDG-PET results. Results: Seventy-seven patients had an available [18F] FDG-PET scan, and 25 (32.5%) had both biomarkers. We observed a fair-to-moderate diagnostic agreement between patients' initial and their final diagnosis in the presence of CSF (κ = 0.233, 95% confidence interval [CI]: -0.099-0.566) and [18F] FDG-PET (κ = 0.451, 95% CI: 0.277-0.625, p < 0.001) results. The Kappa value for diagnostic concordance between [18F] FDG-PET and CSF to differentiate between AD and other dementias was 0.733 (95% CI: 0.425-1.000, p < 0.005). Conclusion: This study demonstrates good agreement between the CSF and FDG-PET biomarkers to differentiate AD from other dementias. (Rev Invest Clin. 2024;76(5):230-7).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 5","pages":"230-237"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Osteoprotegerin and Receptor Activator of Nf-Κb Ligand in Malaysian Male Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study. 评估马来西亚男性慢性阻塞性肺疾病患者的骨保护素和Nf-Κb配体受体激活剂:一项横断面研究。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000192
Bitar Ahmad N, Al-Mansoub Majed A, Syed-Sulaiman Syed A, Saqallah Fadi G, Hyder-Ali Irfhan A B, Alshehade Salah A, Hayat-Khan Amer

Unassigned: Background: Limited information exists regarding the pathophysiological interactions between osteoporosis and chronic obstructive pulmonary disease (COPD). Objective: To study the association of Osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-Β ligand (RANKL) in male COPD patients. Methods: An observational clinical study was conducted at Penang General Hospital in Malaysia. Participants were divided into three groups: COPD patients with osteoporosis, COPD patients without osteoporosis, and healthy participants of the same age groups. Serum OPG (sOPG) and RANKL (sRANKL) levels were investigated. Results: The mean age of COPD patients was 64.10 ± 10.04 years. COPD patients had lower body mass index (23.22 ± 6.43) than healthy participants (27.32 ± 6.80). The T-score was significantly lower among COPD patients than healthy participants (p = 0.018). The sOPG concentration among healthy participants was significantly higher (361.90 ± 29.10 pg/mL, p < 0.001) than in the other groups, while the sRANKL concentration was not significantly different. The serum OPG/RANKL concentration was markedly higher in the control group than in the COPD patient group (p < 0.05). The COPD patients with osteoporosis had significantly lower pulmonary parameters (forced expiratory volume in the first [FEV]1% and FEV1/[forced vital capacity] (FVC), p < 0.01) and more dyspnea (modified medical research council = 2.60 ± 0.78 versus 1.90 ± 0.70, p < 0.01) than did the patients without osteoporosis. Furthermore, patients with severe COPD had a 3 times greater risk of developing osteoporosis (OR = 2.997 [95% CI = 2.181, 4.118], p < 0.001), while spirometric parameters had a significant inverse relationship with osteoporosis (FEV1% OR = 0.970, [95% CI = 0.954, 0.986], p = 0.001; FEV1/FVC OR = 0.984, (95% CI = 0.970, 0.999], p = 0.035). Conclusion: The study concluded that COPD patients had lower sOPG levels, leading to decreased OPG/RANKL ratio and faster bone resorption. Low bone mineral density was associated with more severe COPD. (Rev Invest Clin. 2024;76(6):262-73).

背景:关于骨质疏松症和慢性阻塞性肺疾病(COPD)之间的病理生理相互作用的信息有限。目的:探讨骨保护素(OPG)与核因子κ κ受体激活因子-Β配体(RANKL)在男性COPD患者中的相关性。方法:在马来西亚槟城总医院进行观察性临床研究。参与者被分为三组:合并骨质疏松的COPD患者、无骨质疏松的COPD患者和同年龄组的健康参与者。检测血清OPG (sOPG)和RANKL (sRANKL)水平。结果:COPD患者的平均年龄为64.10±10.04岁。COPD患者的体重指数(23.22±6.43)低于健康受试者(27.32±6.80)。COPD患者的t评分明显低于健康受试者(p = 0.018)。健康组的sOPG浓度(361.90±29.10 pg/mL, p < 0.001)显著高于其他组,而sRANKL浓度无显著差异。对照组血清OPG/RANKL浓度明显高于COPD患者组(p < 0.05)。COPD合并骨质疏松患者肺参数(首发用力呼气量[FEV]1%和FEV1/[用力肺活量](FVC), p < 0.01)明显低于无骨质疏松患者,呼吸困难(修正医学研究委员会= 2.60±0.78比1.90±0.70,p < 0.01)明显高于无骨质疏松患者。此外,重度COPD患者发生骨质疏松的风险是COPD患者的3倍(OR = 2.997 [95% CI = 2.181, 4.118], p < 0.001),肺活量测定参数与骨质疏松呈显著负相关(FEV1% OR = 0.970, [95% CI = 0.954, 0.986], p = 0.001;FEV1/FVC OR = 0.984, (95% CI = 0.970, 0.999), p = 0.035。结论:COPD患者sOPG水平较低,导致OPG/RANKL比值降低,骨吸收加快。低骨密度与更严重的COPD相关。[j] .中国医学工程学报,2009;36(6):662 - 663。
{"title":"Assessment of Osteoprotegerin and Receptor Activator of Nf-Κb Ligand in Malaysian Male Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.","authors":"Bitar Ahmad N, Al-Mansoub Majed A, Syed-Sulaiman Syed A, Saqallah Fadi G, Hyder-Ali Irfhan A B, Alshehade Salah A, Hayat-Khan Amer","doi":"10.24875/RIC.24000192","DOIUrl":"https://doi.org/10.24875/RIC.24000192","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: Limited information exists regarding the pathophysiological interactions between osteoporosis and chronic obstructive pulmonary disease (COPD). Objective: To study the association of Osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-Β ligand (RANKL) in male COPD patients. Methods: An observational clinical study was conducted at Penang General Hospital in Malaysia. Participants were divided into three groups: COPD patients with osteoporosis, COPD patients without osteoporosis, and healthy participants of the same age groups. Serum OPG (sOPG) and RANKL (sRANKL) levels were investigated. Results: The mean age of COPD patients was 64.10 ± 10.04 years. COPD patients had lower body mass index (23.22 ± 6.43) than healthy participants (27.32 ± 6.80). The T-score was significantly lower among COPD patients than healthy participants (p = 0.018). The sOPG concentration among healthy participants was significantly higher (361.90 ± 29.10 pg/mL, p < 0.001) than in the other groups, while the sRANKL concentration was not significantly different. The serum OPG/RANKL concentration was markedly higher in the control group than in the COPD patient group (p < 0.05). The COPD patients with osteoporosis had significantly lower pulmonary parameters (forced expiratory volume in the first [FEV]1% and FEV<sub>1</sub>/[forced vital capacity] (FVC), p < 0.01) and more dyspnea (modified medical research council = 2.60 ± 0.78 versus 1.90 ± 0.70, p < 0.01) than did the patients without osteoporosis. Furthermore, patients with severe COPD had a 3 times greater risk of developing osteoporosis (OR = 2.997 [95% CI = 2.181, 4.118], p < 0.001), while spirometric parameters had a significant inverse relationship with osteoporosis (FEV<sub>1</sub>% OR = 0.970, [95% CI = 0.954, 0.986], p = 0.001; FEV<sub>1</sub>/FVC OR = 0.984, (95% CI = 0.970, 0.999], p = 0.035). Conclusion: The study concluded that COPD patients had lower sOPG levels, leading to decreased OPG/RANKL ratio and faster bone resorption. Low bone mineral density was associated with more severe COPD. (Rev Invest Clin. 2024;76(6):262-73).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 6","pages":"262-273"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Risk Prediction Models in People Living with Human Immunodeficiency Virus under Antiretroviral Therapy in Northern Mexico. 墨西哥北部抗逆转录病毒治疗下人类免疫缺陷病毒感染者心血管风险预测模型
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000176
Urraza-Robledo Arguiñe I, López-Márquez Francisco C, González-Galarza Faviel F, Pere-Pedrol Domingo, Gutiérrez-Pérez María E, Goytia Ana P Roiz-Bollain Y, Ruiz-Flores Pablo, Segura-López Fanny K, Miranda-Pérez Alberto A

Unassigned: Background: The effective use of combination antiretroviral therapy (ART) has significantly improved the life expectancy of people living with the human immunodeficiency virus (HIV). However, complications have shifted from opportunistic infections to issues such as drug toxicity and resistance, as well as an increase in premature cardiovascular diseases (CVD). These conditions are attributed to chronic immune activation and persistent inflammation caused by HIV, along with lipid abnormalities and insulin resistance. Objective: The objective of the study was to predict cardiovascular risk at 5 and 10 years in people living with HIV with combination ART using three algorithmic models. Methods: This study included 186 HIV-seropositive patients under treatment. The variables analyzed included anthropometric measurements, family history of hypertension and CVDs, years of infection, years of treatment, and treatment scheme. We used three well-established algorithmic models for assessing cardiovascular risk: Framingham (10-year period), Data Collection on Adverse Events of Anti-HIV Drugs Study (D: A: D) reduced, and full (5-year period). Results: Approximately 65% of the study participants were undergoing a treatment regimen comprising two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a non-NRTIs. The mean body mass index analysis indicated that 28.5% of the participants were overweight and 17.7% obese. In addition, 53.8% of the patients exhibited hypertriglyceridemia, and 54.8% met the diagnostic criteria for metabolic syndrome. The D: A: D reduced and full models identified significant risk factors for individuals over 30 years of age, highlighting notable associations with cholesterol levels, triglyceride levels, and smoking status. In contrast, the Framingham model did not demonstrate significant risk associations. (Rev Invest Clin. 2024;76(6):274-85).

背景:抗逆转录病毒联合治疗(ART)的有效使用显著提高了人类免疫缺陷病毒(HIV)感染者的预期寿命。然而,并发症已从机会性感染转向药物毒性和耐药性等问题,以及过早心血管疾病(CVD)的增加。这些情况归因于HIV引起的慢性免疫激活和持续炎症,以及脂质异常和胰岛素抵抗。目的:该研究的目的是使用三种算法模型预测联合抗逆转录病毒治疗的艾滋病毒感染者5年和10年的心血管风险。方法:本研究纳入186例正在治疗的hiv血清阳性患者。分析的变量包括人体测量、高血压和心血管疾病家族史、感染年数、治疗年数和治疗方案。我们使用了三种完善的算法模型来评估心血管风险:Framingham(10年期)、抗hiv药物不良事件数据收集研究(D: A: D)减少和完整(5年期)。结果:大约65%的研究参与者正在接受由两种核苷逆转录酶抑制剂(nrti)联合一种非nrti组成的治疗方案。平均身体质量指数分析显示,28.5%的参与者超重,17.7%的参与者肥胖。此外,53.8%的患者表现出高甘油三酯血症,54.8%的患者符合代谢综合征的诊断标准。D: A: D减少和完整模型确定了30岁以上个体的重要风险因素,突出了与胆固醇水平、甘油三酯水平和吸烟状况的显著关联。相比之下,Framingham模型并没有显示出显著的风险关联。[j] .投资与临床,2024;76(6):274-85。
{"title":"Cardiovascular Risk Prediction Models in People Living with Human Immunodeficiency Virus under Antiretroviral Therapy in Northern Mexico.","authors":"Urraza-Robledo Arguiñe I, López-Márquez Francisco C, González-Galarza Faviel F, Pere-Pedrol Domingo, Gutiérrez-Pérez María E, Goytia Ana P Roiz-Bollain Y, Ruiz-Flores Pablo, Segura-López Fanny K, Miranda-Pérez Alberto A","doi":"10.24875/RIC.24000176","DOIUrl":"https://doi.org/10.24875/RIC.24000176","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: The effective use of combination antiretroviral therapy (ART) has significantly improved the life expectancy of people living with the human immunodeficiency virus (HIV). However, complications have shifted from opportunistic infections to issues such as drug toxicity and resistance, as well as an increase in premature cardiovascular diseases (CVD). These conditions are attributed to chronic immune activation and persistent inflammation caused by HIV, along with lipid abnormalities and insulin resistance. Objective: The objective of the study was to predict cardiovascular risk at 5 and 10 years in people living with HIV with combination ART using three algorithmic models. Methods: This study included 186 HIV-seropositive patients under treatment. The variables analyzed included anthropometric measurements, family history of hypertension and CVDs, years of infection, years of treatment, and treatment scheme. We used three well-established algorithmic models for assessing cardiovascular risk: Framingham (10-year period), Data Collection on Adverse Events of Anti-HIV Drugs Study (D: A: D) reduced, and full (5-year period). Results: Approximately 65% of the study participants were undergoing a treatment regimen comprising two nucleoside reverse transcriptase inhibitors (NRTIs) combined with a non-NRTIs. The mean body mass index analysis indicated that 28.5% of the participants were overweight and 17.7% obese. In addition, 53.8% of the patients exhibited hypertriglyceridemia, and 54.8% met the diagnostic criteria for metabolic syndrome. The D: A: D reduced and full models identified significant risk factors for individuals over 30 years of age, highlighting notable associations with cholesterol levels, triglyceride levels, and smoking status. In contrast, the Framingham model did not demonstrate significant risk associations. (Rev Invest Clin. 2024;76(6):274-85).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 6","pages":"274-285"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal Trends in HIV-1 Subtypes and Drug Resistance in Children from Argentina over a 15-Year Period (2006-2021). 阿根廷儿童 15 年间(2006-2021 年)HIV-1 亚型和耐药性的纵向趋势。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000210
Natalia J López, Solange Arazi-Caillaud, Rosa M Bologna, Andrea M Mangano, Paula C Aulicino

Background: Human immunodeficiency virus (HIV) drug resistance is a major cause of treatment failure in children and adolescents infected with the virus.

Objectives: The objectives of the study are to investigate HIV drug resistance (HIVDR) in patients who attended a referral care center in Argentina over a 15-year period and to compare mutational patterns between HIV-1 polsequences characterized as B or BF recombinants.

Methods: Individual resistance-associated mutations (RAMs) (to protease and reverse transcriptase inhibitors) were identified according to IAS-USA guidelines in 374 HIV-1-infected children and adolescents. HIV-1 subtype was characterized by phylogenetic and recombination analysis using MEGA5.1 and Simplot. Poisson linear regression was used to model the dynamics of the RAMs over time.

Results: The prevalence of RAMs to protease inhibitors (R2 = 0.52, p = 0.0012) and nucleoside reverse transcriptase inhibitors (R2 = 0.30, p = 0.0225) decreased over time. HIVDR to non-nucleoside reverse transcriptase inhibitors remained moderate to high, ranging between 33% and 76%. BF recombinants showed a higher frequency of thymidine analog mutation 1 RAMs profile and I54V mutation.

Conclusion: In Argentina, HIVDR observed in children and adolescents has decreased over the past 15 years, regardless of the viral subtype. (REV INVEST CLIN. 2024;76(1):29-36).

未分配:背景:人类免疫缺陷病毒(HIV)耐药性是感染该病毒的儿童和青少年治疗失败的主要原因。研究目的本研究的目的是调查阿根廷一家转诊护理中心 15 年间就诊患者的 HIV 耐药性(HIVDR),并比较被定性为 B 型或 BF 型重组病毒的 HIV-1 多序列之间的变异模式。方法根据 IAS-USA 指南,在 374 名感染 HIV-1 的儿童和青少年中确定了单个耐药性相关突变(RAM)(对蛋白酶和逆转录酶抑制剂)。通过使用 MEGA5.1 和 Simplot 进行系统发育和重组分析,确定了 HIV-1 亚型的特征。泊松线性回归用于模拟 RAMs 随时间变化的动态变化。结果显示蛋白酶抑制剂(R2 = 0.52,p = 0.0012)和核苷酸逆转录酶抑制剂(R2 = 0.30,p = 0.0225)的 RAM 流行率随时间推移而下降。对非核苷类逆转录酶抑制剂的 HIVDR 仍保持在中高水平,介于 33% 与 76% 之间。BF 重组株出现胸苷类似物突变 1 RAMs 特征和 I54V 突变的频率较高。结论在阿根廷,无论病毒亚型如何,过去 15 年中在儿童和青少年中观察到的 HIVDR 均有所下降。(Rev invest clin.2024;76(1):29-36).
{"title":"Longitudinal Trends in HIV-1 Subtypes and Drug Resistance in Children from Argentina over a 15-Year Period (2006-2021).","authors":"Natalia J López, Solange Arazi-Caillaud, Rosa M Bologna, Andrea M Mangano, Paula C Aulicino","doi":"10.24875/RIC.23000210","DOIUrl":"10.24875/RIC.23000210","url":null,"abstract":"<p><strong>Background: </strong>Human immunodeficiency virus (HIV) drug resistance is a major cause of treatment failure in children and adolescents infected with the virus.</p><p><strong>Objectives: </strong>The objectives of the study are to investigate HIV drug resistance (HIVDR) in patients who attended a referral care center in Argentina over a 15-year period and to compare mutational patterns between HIV-1 polsequences characterized as B or BF recombinants.</p><p><strong>Methods: </strong>Individual resistance-associated mutations (RAMs) (to protease and reverse transcriptase inhibitors) were identified according to IAS-USA guidelines in 374 HIV-1-infected children and adolescents. HIV-1 subtype was characterized by phylogenetic and recombination analysis using MEGA5.1 and Simplot. Poisson linear regression was used to model the dynamics of the RAMs over time.</p><p><strong>Results: </strong>The prevalence of RAMs to protease inhibitors (R2 = 0.52, p = 0.0012) and nucleoside reverse transcriptase inhibitors (R2 = 0.30, p = 0.0225) decreased over time. HIVDR to non-nucleoside reverse transcriptase inhibitors remained moderate to high, ranging between 33% and 76%. BF recombinants showed a higher frequency of thymidine analog mutation 1 RAMs profile and I54V mutation.</p><p><strong>Conclusion: </strong>In Argentina, HIVDR observed in children and adolescents has decreased over the past 15 years, regardless of the viral subtype. (REV INVEST CLIN. 2024;76(1):29-36).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 1","pages":"29-36"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140040760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista De Investigacion Clinica-Clinical and Translational Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1